263 related articles for article (PubMed ID: 30912213)
21. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
Roach P; Malone JK
Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
[TBL] [Abstract][Full Text] [Related]
22. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
23. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study).
Watada H; Su Q; Li PF; Iwamoto N; Qian L; Yang WY
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155890
[TBL] [Abstract][Full Text] [Related]
24. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50.
Gao Y; Li G; Li Y; Guo X; Yuan G; Gong Q; Yan L; Zheng Y; Zhang J
Int J Clin Pract; 2008 Sep; 62(9):1344-51. PubMed ID: 18657196
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
[TBL] [Abstract][Full Text] [Related]
26. Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes.
Liu BL; Liu XM; Ren YF; Sun YX; Luo MH; Ye L; Ma JH; Li FF
J Diabetes Res; 2020; 2020():8152640. PubMed ID: 32090123
[TBL] [Abstract][Full Text] [Related]
27. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
28. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
Roach P; Trautmann M; Arora V; Sun B; Anderson JH
Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
[TBL] [Abstract][Full Text] [Related]
30. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): Subgroup analysis of a Phase 4 open-label randomized trial.
Su Q; Liu C; Zheng H; Zhu J; Li PF; Qian L; Yang WY
J Diabetes; 2017 Jun; 9(6):575-585. PubMed ID: 27371341
[TBL] [Abstract][Full Text] [Related]
31. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
32. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A
Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
[TBL] [Abstract][Full Text] [Related]
33. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients.
Shimizu H; Monden T; Matsumura M; Domeki N; Kasai K
Yonsei Med J; 2010 Nov; 51(6):845-9. PubMed ID: 20879049
[TBL] [Abstract][Full Text] [Related]
34. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
35. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE
Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of once or twice daily neutral protamine hagedorn insulin in fasting pregnant women with diabetes during Ramadan.
Nor Azlin MI; Adam R; Sufian SS; Wahab NA; Mustafa N; Kamaruddin NA; Jamil MA
J Obstet Gynaecol Res; 2011 Feb; 37(2):132-7. PubMed ID: 21159037
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Vignati L; Anderson JH; Iversen PW
Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
[TBL] [Abstract][Full Text] [Related]
38. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
[TBL] [Abstract][Full Text] [Related]
39. Achieving safer Ramadan fasting by keeping flexible glycemic targets during the day and tighter targets during the night in insulin treated people with type 2 diabetes.
Ahmedani MY; Ghafoor E
Diabetes Res Clin Pract; 2020 Jul; 165():108234. PubMed ID: 32450103
[TBL] [Abstract][Full Text] [Related]
40. Effect of a new insulin treatment regimen on glycaemic control and quality of life of Muslim patients with type 2 diabetes mellitus during Ramadan fast - an open label, controlled, multicentre, cluster randomised study.
Shehadeh N; Maor Y;
Int J Clin Pract; 2015 Nov; 69(11):1281-8. PubMed ID: 26234442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
